The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Gift Disclosure and Registration Tom Tremble, AdvaMed Julie Cohen, AdvaMed.

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

PwC Medical Device Compliance Survey Discussion of Survey Results.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
CTE / Companion Upgrade Office of Ethics and Compliance December 21, 2011.
1 UMass Dartmouth Conflicts of Interest Policies UMass Dartmouth Liz Rodriguez February 17, 2011.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
COMPLIANCE AND INTEGRITY IN GOVERNMENT AND NON-PROFIT ORGANIZATIONS Michael E. Nawrocki, CPA Managing Partner Nawrocki Smith LLP, CPA’s Historical Perspective.
Chapter 43 An Act Relative to Improving Accountability and Oversight of Education Collaboratives Presentation to Board of Elementary and Secondary Education.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
Sarbanes-Oxley Compliance Process Automation
Minnesota Law and Health Information Exchange Oversight Activities James I. Golden, PhD State Government Health IT Coordinator Director, Health Policy.
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
Internal Auditing and Outsourcing
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Health Care Reform and Concordia Plan Services 2012.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
State Ethics & Lobbying Laws for Pharmaceutical and Medical Device Companies John T. Bentivoglio (202) Steve Benz
©2008 Office of Massachusetts Attorney General Martha Coakley Community Benefits Guidelines Office of Attorney General Martha Coakley February 23, 2009.
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
Best Practices: Financial Resource Management February 2011.
July 31, 2009Prepared by the Maine Health Information Center Overview of All Payer Claims Data Suanne Singer, Senior Consultant Maine Health Information.
1 Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health PHC Meeting.
Transparency in Grants and Gifts Pfizer Approach Cathryn Clary, MD VP, US External Medical Affairs.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
OPEN PAYMENTS UF College of Medicine Brown Bag July 23, 2013 Gary Wimsett, Jr., JD.
Understanding the Forces Driving Disclosure Preconference Session First Annual Summit on Sales & Marketing Disclosure for Drug, Device and Biotech Companies.
© Huron Consulting Services LLC. All rights reserved. Aggregate Spend 101 March 5, 2009 L I F E S C I E N C E S A D V I S O R Y S E R V I C E S Manny Tzavlakis.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference Questions: Legal/Regulatory & Operational Considerations March 5, 2009.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
WHAT STAKEHOLDERS NEED TO KNOW ABOUT THE CME/SUNSHINE ACT PROVISION OF THE ‘21 ST CENTURY CURES ACT’ JULY 14,
Managing Risk with Third Parties and Strategic Partners State Law Compliance The Overview November 8, 2007 Pharmaceutical Regulatory and Compliance Congress.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
DGS Recommendations to the Governor’s Task Force on Contracting & Procurement Review Report Overview August 12, 2002.
COCIR Code of Conduct Nicole DENJOY COCIR Secretary General.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
Fund Balance Policy Actions/Procedures Dr. Rodney Thompson, Superintendent Mr. Brantley Thomas, Chief Financial Officer September 23, 2014 Berkeley County.
HIPAA History March 3, HIPAA Ruling Health Insurance Portability Accountability Act Health Insurance Portability Accountability Act Passed by Congress.
1 Strategic Plan Review. 2 Process Planning and Evaluation Committee will be discussing 2 directions per meeting. October meeting- Finance and Governance.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
PwC National disclosure audio conference: Analysis of the revised Physician Payments Sunshine Act and state drug marketing laws February 10, 2009 “Where.
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
California’s New Compliance Law Kelly N. Reeves
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
An Unprecedented Opportunity: Using Federal Stimulus Funds to Advance Health IT in California Testimony of Sam Karp, Vice President of Programs California.
Copyright © Texas Education Agency Accounting for Grant Funds, including Documentation for Expenditures.
© 2014 By Katherine Downing, MA, RHIA, CHPS, PMP.
1 The Implementation of Fair Market Value What can we learn from recent enforcement actions? Debjit Ghosh Life Sciences Advisory Services Huron Consulting.
Making Healthcare Affordable
Lilly Grant Funding Disclosure May 27, 2008
California’s “Comprehensive Compliance Program” Law
Pharmacy – Fully Insured versus Self Funding
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Coalition Sample Code of Ethics
Benchmarking Compliance for the Healthcare Industry
Analysis of the Proposed Sunshine Rule Implementation Issues
Presentation transcript:

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Gift Disclosure and Registration Tom Tremble, AdvaMed Julie Cohen, AdvaMed Vickie McCormick, St. Jude Medical Debjit Ghosh, Huron Consulting Group, LLC March 27, 2008

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Overview of State Legislative Activity Presented by Tom Tremble AdvaMed

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Overview of State Legislative Activity Background Current Proposals What’s Driving Them Outlook

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Overview of State Legislative Activity  Background Enacted Laws  ReportingRegistration/certification  Minnesota (1993)California (2004)  Vermont (2005)Nevada (2007)  Maine (2004)  District of Columbia (2004)  West Virginia (2004)

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Overview of State Legislative Activity Bans – Minnesota—prohibits gifts of $50 or more Exceptions: – Samples, conferences, honoraria, and faculty. – Device companies that distribute drugs as an incidental part of business Separate MN provision requiring annual report of payments totaling $100 or more to individual practitioners Reporting Provisions – DC, ME, and VT require reporting of gifts over $25.00

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Registration Requirements California SB1765 Signed by Governor 9/29/04 Requires a pharmaceutical company to adopt a comprehensive compliance program in accord with the OIG guidelines Companies are to include provisions for complying with the PhRMA Code CCP to include limits on gifts or incentives provided to medical or health professionals CCP to include a specific dollar limit for gifts to individual physicians Exempts samples, conference support, and scholarships Defines “dangerous drug” as drugs and device(s) that may be dispensed only by prescription

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Registration Requirements Nevada – Requires drug and device manufacturers and wholesalers to adopt a marketing code of conduct that addresses: Basis for interactions, informational presentations, third-party educational meetings, use of consultants, scholarships, and educational items By June 1 every year, device firms are to notify the NV Board of Pharmacy of their code of conduct and should indicate if they are adhering to the AdvaMed Code.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Overview of State Legislative Activity Recent and Current Activity ▪ District of Columbia Safe RX Act of 2007 ▪ Massachusetts S2535 ▪ Washington ▪ New Jersey Attorney General Task Force on Physician Compensation ▪ New Hampshire HB1518 ▪ Tennessee HB3602/HB2677 Who and What’s Driving It ▪ Consumers Union, AARP, NLARx, Ortho Outlook

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Discussion of Physician Payment Sunshine Legislation Presented by Julie Cohen AdvaMed

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Environment on Capitol Hill Democratic Majority in Congress made pharmaceutical pricing, influence, safety and transparency a top priority issue Medical devices are increasingly included in scrutiny of industry practices. Congressional Budget Office hearings/reports/statements about the influence of medical technology in driving overall health care cost increases Oversight hearings on FDA’s ability to carry out its mission Passage of 2007 Ethics/Lobbying Disclosure Legislation

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Recent Congressional Activity on Gift Disclosure June 2007 – Senate Aging Committee hearing on Drug Industry Payments to Physicians – chaired by Senator Herb Kohl (D-WI) July 2007 – Rep. Peter Defazio (D-OR) introduced H.R. 3023, Drug and Medical Device Company Gift Disclosure Act September 2007 – Senators Grassley (R-IA) and Kohl introduced S. 2029, Physician Payments Sunshine Act Efforts by Grassley-Kohl to include “Sunshine” Act in Medicare legislation in Fall 2007 February 27, 2008 – Senate Aging Committee hearing on Device Industry Payments to Physicians

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Grassley-Kohl legislation (S.2029) Requires all manufacturers of drugs, devices, and medical supplies, with annual gross revenues of more than $100 million, to disclose any payment above $25, quarterly and in an annual summary report Must disclose all payments, including compensation, food, entertainment, gifts, trips or travel, discounted products, continuing medical education, product rebates, consulting fees or any other economic benefit as defined by the Secretary. Product rebates and discounts specifically included Covered health care professionals include physicians or an entity a physician is employed by, has tenure with or an ownership interest Exceptions include free drug samples for patients, payments for clinical trials Penalties for non-compliance: minimum $10,000 up to $100,000 per violation

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress AdvaMed’s Key Advocacy Points Collaboration with health care professionals is essential to invent and improve medical devices, and to ensure health care professionals are trained to use devices safely and effectively AdvaMed has embraced a strong Code of Ethics to preserve collaborations with health care professionals With some key changes to the legislation – to ensure a fair and level playing field, provide clear and meaningful information to patients, and to preserve relationships that benefit patients and innovation – AdvaMed could support the legislation.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Understanding Collaborative Relationships Between the Medical Device Industry and Physicians Physicians are key partners in the development and improvement of medical technology - Innovation requires ongoing collaboration to improve technology for patients - Partners in invention, development, clinical testing, education/training, providing feedback for improvements Physician training is a critical component in the safe and effective use of medical devices - Physician technique/skills are critical with medical devices. - Hands-on training is essential. Physician collaboration with the device industry has led to ground-breaking advances in patient care

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress AdvaMed Has Embraced a Strong Code of Ethics to Preserve Collaboration with Health Care Professionals The medical device industry recognizes that strong ethical standards is critical to our ability to continue collaborative relationships Our Code of Ethics, effective January 1, 2004, distinguishes bona fide interactions that benefit patients from those that may influence medical decisions inappropriately We have aggressively promoted adoption of the code with members and health care professionals An independent 2006 survey found nearly 100% compliance among members surveyed The Code addresses training and education, consulting, support of third- party educational conferences, sales and promotion, gifts, grants and charitable contributions AdvaMed member companies take the Code further with dedicated resources and additional compliance procedures

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress AdvaMed’s Position on S AdvaMed supports appropriate disclosure of relationships between medical technology companies and physicians We could support the legislation if key changes are made to ensure a fair and level playing field, provide clear and meaningful information to patients, and to preserve relationships that benefit patients and innovation – Preemption: create one uniform, strong Federal standard – Alternative threshold: companies that make more than $250,000 in annual reportable payments to physicians should disclose – Physician-owned entities should be included – Context of relationships should be provided to patients

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Additional Legislative Changes Sought by AdvaMed Instead of reporting “transfers of value,” legislation should enumerate specific types of payments to be disclosed Delayed disclosure of product development agreements/clinical trials to protect proprietary information Exclude reporting of discounts, rebates, and other pricing information Exclude reporting of warranties, technical support, reimbursement information, and device samples/models for provider and patient demonstration (continued)

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Additional Legislative Changes Sought by AdvaMed Require reporting for education and training to be limited to the value of meals, travel, and compensation only – rather than imputing a value to the training itself Provide two years before implementation to allow companies to develop or refine tracking systems Require annual reporting instead of quarterly reporting Cap penalties Allow reporting of payments in dollar ranges or bands

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Legislative Prospects for 2008 Sponsors are considering revisions to the legislation New House bill expected to be introduced that more closely aligns with S.2029 Medicare legislation expected in first half of 2008 – sponsors are well- positioned and will likely seek to attach S.2029 AdvaMed doing outreach to Hill offices to advocate for key recommendations to improve the legislation

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Discussion of Aggregate Spend Tracking Challenges – Key Operational Issues Presented by Vickie McCormick St. Jude Medical Djebit Ghosh Huron Consulting Group, LLC

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Defining the Data Integration Challenge ERP System SFA Grants T&E KOL Tracking Investigator Trial Activity Investigator Trial Activity For Illustrative Purposes Designed to facilitate enterprise finance and logistic functions. Designed to track sales force contacts and prescription activity. Designed to track grant payments and activity milestones for recipients. Designed to accurately reimburse employees for expenses incurred. Designed to track Medical Affairs contacts with KOLs and Investigators. Designed to track milestones and payments for Investigator Trials. Systems for most Medical Device Companies are designed to meet very specific needs of functional areas within the company (e.g., sales, clinical, finance, etc.)

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Changing the Paradigm for Data Tracking Tracking spending on healthcare professionals (“HCP”) requires accurate and complete data integration across key legacy systems The need to integrate data at the transactional level across enterprise systems has not been a previous focus of medical device IT departments Data across multiple systems cannot be accurately and completely integrated without the ability to identify transactions at the HCP level Every transaction must be identifiable and attributable to an individual HCP for aggregation, tracking, and reporting (aggregate spend) Key Points for Consideration Measuring General Effects Accuracy and Completeness

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Tracking and Disclosure is a “Bottom-Up” Process The transactional data must be in a form that can be used for “aggregate spend tracking” purposes – If a record for a “trackable” expense does not have adequate and identifiable information (e.g. value, nature, purpose, recipient, identifier, etc.), identifying the details of the transaction and the individual later in the process becomes significantly more difficult – Rather than receiving an accurate record of the HCP from the source system or the individual responsible for the expense or activity, a “downstream” system or process will have the burden of identifying the transaction Solving the data integration challenge requires a data capture approach that will be sufficiently flexible, scalable, and adaptable to integrate transactional data across multiple source systems – Although an Enterprise Level Customer Master Strategy is generally the most effective approach, it is not always feasible – The cost of changing enterprise systems or adding functionality may be insurmountable – Disruption to company operations can range from being minimal with “buy-in” from functional areas or excessive if functional areas do not cooperate

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Identifying all HCP “Touch Points” Identifying all of the HCP “touch points” across the enterprise is a critical step in defining a data capture approach Incomplete data from a functional area or the inability to integrate a data source will likely result in non-compliance Companies should consider both direct and in-direct (third party payments) in developing a data capture approach Transactional Data: Unique HCP Identifier Product Association Value Nature Purpose For Illustrative Purposes Marketing Commercial & Managed Care Commercial & Managed Care Clinical & Medical Affairs Clinical & Medical Affairs Direct Payments Third Party & Indirect Payments Third Party & Indirect Payments Speakers & Consultants Advisory Boards Grants Meals & Gifts Investigator Activities Sales Force Marketing Commercial & Managed Care Contracting Clinical & Medical Affairs Clinical & Medical Affairs Direct Payments Third Party & Indirect Payments Third Party & Indirect Payments Speakers & Consultants Advisory Boards Grants, Royalties, & IP Payments Meals, Travel, Lodging & Gifts Investigator Activities Sales Force

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Defining an Enterprise Customer Master The goal of an enterprise level customer master strategy is to identify unique HCPs at the time of the transaction or at a later time in order to facilitate tracking and reporting Integrating an enterprise customer master into individual source systems will present unique challenges and requirements Customer Master File Key Challenges Maintaining accurate and timely customer data Linking the same HCP across multiple systems (matching) Complete and accurate reference data identifying key data attributes such as state licensure, affiliations, tax information, etc. Key Challenges Maintaining accurate and timely customer data Linking the same HCP across multiple systems (matching) Complete and accurate reference data identifying key data attributes such as state licensure, affiliations, tax information, etc.

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Key Considerations in Developing a ECM (1) Development and maintenance of a customer master file – Multiple practices – Institutional affiliations – Multiple addresses – Multiple Tax IDs – Name Changes – Multiple State License Numbers Managing multiple HCP types – Physicians – Mid-Levels (NP, PA, RPh, etc.) – Hospitals and ambulatory surgical centers – Academic institutions

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Key Considerations in Developing a ECM (2) Managing history – Identifying data elements can change from year to year. – History should be maintained for audit and tracking purposes. – Develop “cross-walks” for multiple affiliations or duplicate records Use of reference data – Third party vendors – National Provider ID (HIPAA mandated)

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Interfacing an ECM with Enterprise Systems ERP System – Typically accounts payable functions – Accurate name, address, and tax ID SFA System – “Call plan” synchronization – “Cross-walk” to sales data Grants System – Customer master data for institutions – “Back-end” linkage to HCP T&E System – Would require “current” data from customer master for HCP selection – Transactional level allocations KOL Tracking – Typically used only by Medical Affairs/MSL force – Tracking of fee-for-service activities Investigator Study Tracking – Part of an overall “aggregate spend tracking” strategy For Illustrative Purposes

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Challenges in Implementing Aggregate Spend Capture Processes

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Changing Systems and Business Processes Effective data capture at the “front end” is the only reasonable strategy to improve accuracy and completeness of aggregate spend data – However, integrating a customer master strategy into existing legacy systems and business processes is a significant challenge Existing processes and systems may not be able to support enhancements to core transaction sets that have been designed to meet very specific functional requirements: – ERP – T&E – KOL Contact Management Portals – Grants Management Systems – Investigator Study Management Systems Organizations should assess their exposure and risk tolerance in assessing the need to change or enhance core systems or business processes – Pareto’s principle of “80/20” may apply in assessing exposure and risk

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Discussion of Core Challenges The integration of a customer master strategy into the Company’s T&E system can be a significant effort. Integrated customer master functionality within the T&E system can reduce significant manual reconciliation and data entry efforts while substantially increasing accuracy and completeness of core data. Travel and Expense (T&E) Systems T&E Data Entry T&E System ERP A/P Function ERP A/P Function Customer Master File Customer Master File Which customer master? Who maintains it and how are updates handled? Exception processing? How are allocations handled? Universe Optimization?

The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Developing a Scalable Process Many organizations use manual processes to integrate data across functional areas For aggregate spend tracking to be truly scalable, a systems based approach must be developed where source data can be automatically loaded into a relational database Data Integration and Warehousing Accounts Payable T & E System Investigator Pmts Third Party Vendors Integrating Data Across Multiple Sources ETL Functionality ETL Functionality Data Staging Aggregate Spend Tracking Database Reporting Functionality Reporting Functionality